Tempus AI, Inc. TEM
2 targets with a reported result
Releases of the last 3 yearsThe numbers TEM said it expected, in its earnings releases, next to what it then reported for the same period.
Target by target
Each target, with the sentence it came from · release and 10-Q or 10-K
| Target | What the company said | Reported | Result | |
|---|---|---|---|---|
| Revenue Fiscal 2026 |
Given $1.59B release Feb 24, 2026
Raised $1.59B to $1.60B release May 5, 2026
Raised $1.59B to $1.60B release Jul 30, 2026
Raised $1.60B to $1.60B release Nov 2, 2026
|
– | Not reported yet | |
The company's wordsRevenue guidance of $1.59 billion for 2026 and expect full year 2026 Adjusted EBITDA of approximately $65 million release Feb 24, 2026 Increasing revenue guidance to $1.59 to $1.60 billion for 2026 and expect full year 2026 Adjusted EBITDA of approximately $65 million release May 5, 2026 Increasing revenue guidance to $1.595 to $1.605 billion for 2026 and expect full year Adjusted EBITDA of ~$65 million release Jul 30, 2026 Increasing full year 2026 revenue guidance to $1.60 to $1.605 billion and expect full year Adjusted EBITDA of ~$65 million release Nov 2, 2026 | ||||
| EBITDA (company-defined) Fiscal 2025 (ended Dec 31, 2025) |
Given $5.00M release May 6, 2025
Kept $5.00M release Aug 8, 2025
|
– | No standard number | |
The company's wordsExpect positive Adjusted EBITDA of $5 million for full year 2025, increasing approximately $110 million over 2024 release May 6, 2025 Increasing full year 2025 revenue guidance to $1.26 billion, along with positive adjusted EBITDA of $5 million, a $110 million improvement over 2024 release Aug 8, 2025 | ||||
| Revenue Fiscal 2025 (ended Dec 31, 2025) |
Given $1.24B release Feb 24, 2025
Raised $1.25B release May 6, 2025
Raised $1.26B release Nov 4, 2025
|
$1.27B 10-K filed 2026-02-24 |
Above the range | |
The company's wordsTempus now expects full year 2025 revenue of approximately $1.24 billion for the consolidated Tempus and Ambry Genetics business, which represents approximately 79% annual growth, and Adjusted EBITDA of $5 million for full year 2025, an improvement of approximately $110 million over 2024. release Feb 24, 2025 (1) Not meaningful due to the impact of including stock compensation expense and related employer payroll taxes Financial Outlook and Guidance Tempus now expects full year 2025 revenue of approximately $1.25 billion for the consolidated Tempus and Ambry Genetics business, which represents approximately 80% annual growth, and Adjusted EBITDA of $5 million for full year 2025, an improvement of approximately $110 million over 2024. release May 6, 2025 Financial Outlook and Guidance Tempus increased full year 2025 revenue guidance to approximately $1.265 billion, which represents ~80% annual growth. release Nov 4, 2025 | ||||
| Revenue Fiscal 2024 (ended Dec 31, 2024) |
Given $700.00M release Aug 6, 2024
Kept $700.00M release Nov 4, 2024
|
$693.40M 10-K filed 2025-02-24 |
Below the range | |
The company's wordsFinancial Outlook and Guidance Tempus expects full year 2024 revenue of approximately $700 million, which represents approximately 32% year-over-year growth. release Aug 6, 2024 Tempus continues to expect full year 2024 revenue of approximately $700 million, which represents approximately 32% year-over-year growth and approximately ($105 million) in adjusted EBITDA, an improvement of approximately $50 million over 2023. release Nov 4, 2024 | ||||
Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (12 releases since 2024-08-06), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.
Sources
The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.
Also
Earnings releases: each release in full.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/TEM/export.csv") into a cell.